Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BYLIEVE
NL-OMON52978Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of alpelisib, fulvestrant and letrozole in breast cancer (3 cohorts), sponsored by Novartis. Primary endpoint: Progression-free survival at 6 months. Started Feb 2018; status: completed.
02
Drugs
alpelisibfulvestrantletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON52978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52978.